Strategists at HSBC led by Frank Lee lowered their price target on the shares to $110 from $200 and cut the rating to Reduce ...

Chip maker AMD is investing $20 million in AI drug startup Absci, which will use AMD chips and software for drug development.

Advanced Micro Devices shares extended their recent run of declines Wednesday after a top Wall Street analyst cautioned that ...

We recently compiled a list of the 10 Hottest Large-Cap Stocks Right Now. In this article, we are going to take a look at ...

It's clear that AMD isn't the AI company Nvidia is. Its $3.5 billion in data center revenue in Q3 was a fraction of Nvidia's ...

The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other industries.

Absci (ABSI) was rising after a media report on a $20M investment by the semiconductor company Advanced Micro Devices (AMD) in the AI drug creation company.

Advanced Micro Devices rose 3% today following news of Microsoft’s substantial investment in AI infrastructure. This development is expected to benefit AMD as a supplier of graphics processing ...

On the other hand, Wall Street has seemingly left Advanced Micro Devices (NASDAQ: AMD) in the dust. While Nvidia has soared an impressive 170% over the past 12 months, AMD has declined nearly 20%.

DiCarlo expressed his bullish outlook on AMD stock in a post on X today. Morgan Stanley analysts have lowered their price target for Advanced Micro Devices from $169 to $158 while maintaining an ...

AMD has room to thrive in an AI chip market ... The Motley Fool has positions in and recommends Advanced Micro Devices, Meta Platforms, Microsoft, and Nvidia. The Motley Fool recommends the ...